Clinical Trial Update: Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BI 695501, a biosimilar, with Humira in moderate to severe chronic plaque psoriasis assessed for efficacy, safety, and immunogenicity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• BI 695501
• Humira (adalimumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-02-08